<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843191</url>
  </required_header>
  <id_info>
    <org_study_id>KSCP2016</org_study_id>
    <nct_id>NCT02843191</nct_id>
  </id_info>
  <brief_title>Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy</brief_title>
  <official_title>KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Society of ColoProctology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyung Hee University Hospital at Gangdong</source>
  <brief_summary>
    <textblock>
      This trial is to assess the efficacy and feasibility of consolidation chemotherapy after
      neoadjuvant chemoradiotherapy for locally advanced mid or low rectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>2 years</time_frame>
    <description>Pathologic complete response is defined as no residual tumor on the surgical specimen after chemoradiotherapy. (i.e. Mandard grade 1 or Dworak grade 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy-related complications</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection</measure>
    <time_frame>2 years</time_frame>
    <description>R0 resection is defined as resection without remnant tumor, whereas R1 resection as microscopic residual tumor and R2 resection as gross residual tumor. R0 resection will be proven histologically as no resection margin involvement of tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Amount of tumor regression after surgery according to the guideline including Mandard or Dworak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy</measure>
    <time_frame>3 years</time_frame>
    <description>Peripheral neuropathy will be evaluated as grade 1 to 4 according to NCI CTCAE 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>5-FU, Leucovorine, and Oxaliplatin (FOLFOX regimen)</description>
    <arm_group_label>Adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Consolidation chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of mid or low rectum

          2. Locally advanced rectal cancer confirmed by image (i.e. Magnetic resonance image)

               -  Clinical stage T1-3N1or2 on MRI

               -  Clinical stage cT3N0 (or depth of perirectal invasion by tumor &gt;5mm on MRI)

               -  Suspicious of circumferential invasion on MRI (or circumferential margin &lt;1mm)

          3. ECOG performance status of 0-2

          4. ASA grade ≤ 3

          5. An informed consent has been signed by the patient

        Exclusion Criteria:

          1. Upper rectal cancer

          2. Clinical stage T1or2N0 on MRI

          3. Clinical stage T4Nany on MRI

          4. Clinical stage TanyNanyM1 by image or histology

          5. The patient received chemotherapy or radiotherapy during the past 6 months

          6. The patient received any therapy for colorectal cancer or another malignancy during
             the past 5 years

          7. The patient has severe underlying diseases or poor condition to receive chemotherapy
             or radiotherapy

          8. Pregnant of breastfeeding women

          9. The patient who participate in another clinical trial, or receives any drug for the
             trial

         10. Uncontrolled peripheral neuropathy (more than grade 2)

         11. Any unhealed wound, fracture, peptic ulcer, or intraabdominal abscess

         12. Active gastrointestinal bleeding

         13. Patients with an active infection, which needs antibiotic therapy, during the
             randomization period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk-Hwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>892 Dongnam-ro, Gangdong-gu, Seoul, Korea. Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Woo Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>892 Dongnam-ro, Gangdong-gu, Seoul, Korea. Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suk-Hwan Lee, MD, PhD</last_name>
    <phone>+82-440-7044</phone>
    <email>leeshdr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chang Woo Kim, MD</last_name>
    <phone>+82-440-6222</phone>
    <email>kcwgkim@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inje University Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Sung An, MD</last_name>
      <phone>82-10-2863-8283</phone>
      <email>gsams@paik.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Byung-Noe Bae, MD</last_name>
      <phone>82-10-6215-6566</phone>
      <email>bnbae1@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Byung-Noe Bae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Sung An, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital, Hallym University College of Medicine</name>
      <address>
        <city>Chuncheon</city>
        <zip>24253</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Mo Kang, MD</last_name>
      <phone>82-10-8586-6963</phone>
      <email>kbm0728@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Byung Mo Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woon Kyung Jeong, MD</last_name>
      <phone>82-10-2535-8440</phone>
      <email>shinycloud@daum.net</email>
    </contact>
    <contact_backup>
      <last_name>Seong Kyu Baek, MD</last_name>
      <phone>82-10-8745-2317</phone>
      <email>sgbeak@dsmc.or.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Seong Kyu Baek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Woon Kyung Jeong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Soo Kim, MD</last_name>
      <phone>82-10-8887-7562</phone>
      <email>jskim7562@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ji Yeon Kim, MD</last_name>
      <phone>82-10-9414-6909</phone>
      <email>jkim@cnu.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Ji Yeon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Soo Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.</citation>
    <PMID>15496622</PMID>
  </reference>
  <reference>
    <citation>Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986 Jun 28;1(8496):1479-82.</citation>
    <PMID>2425199</PMID>
  </reference>
  <reference>
    <citation>Kapiteijn E, Kranenbarg EK, Steup WH, Taat CW, Rutten HJ, Wiggers T, van Krieken JH, Hermans J, Leer JW, van de Velde CJ. Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J Surg. 1999 May;165(5):410-20.</citation>
    <PMID>10391155</PMID>
  </reference>
  <reference>
    <citation>van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011 Jun;12(6):575-82. doi: 10.1016/S1470-2045(11)70097-3. Epub 2011 May 17.</citation>
    <PMID>21596621</PMID>
  </reference>
  <reference>
    <citation>Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006 Oct 1;24(28):4620-5.</citation>
    <PMID>17008704</PMID>
  </reference>
  <reference>
    <citation>Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1;30(16):1926-33. doi: 10.1200/JCO.2011.40.1836. Epub 2012 Apr 23.</citation>
    <PMID>22529255</PMID>
  </reference>
  <reference>
    <citation>Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985 Jun 6;312(23):1465-72.</citation>
    <PMID>2859523</PMID>
  </reference>
  <reference>
    <citation>Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.</citation>
    <PMID>16971718</PMID>
  </reference>
  <reference>
    <citation>Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009 Nov 1;27(31):5124-30. doi: 10.1200/JCO.2009.22.0467. Epub 2009 Sep 21.</citation>
    <PMID>19770376</PMID>
  </reference>
  <reference>
    <citation>Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001 Aug 30;345(9):638-46.</citation>
    <PMID>11547717</PMID>
  </reference>
  <reference>
    <citation>Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74.</citation>
    <PMID>12062610</PMID>
  </reference>
  <reference>
    <citation>Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005 Dec 1;23(34):8688-96. Epub 2005 Oct 24.</citation>
    <PMID>16246976</PMID>
  </reference>
  <reference>
    <citation>Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994 Jun 1;73(11):2680-6.</citation>
    <PMID>8194005</PMID>
  </reference>
  <reference>
    <citation>García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003 Mar;46(3):298-304.</citation>
    <PMID>12626903</PMID>
  </reference>
  <reference>
    <citation>Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19-23.</citation>
    <PMID>9112145</PMID>
  </reference>
  <reference>
    <citation>Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010 Apr 1;28(10):1638-44. doi: 10.1200/JCO.2009.25.8376. Epub 2010 Mar 1.</citation>
    <PMID>20194850</PMID>
  </reference>
  <reference>
    <citation>Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011 Jul 10;29(20):2773-80. doi: 10.1200/JCO.2010.34.4911. Epub 2011 May 23.</citation>
    <PMID>21606427</PMID>
  </reference>
  <reference>
    <citation>Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Seitz JF, Bedenne L, Juzyna B, Conroy T. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012 Dec 20;30(36):4558-65. doi: 10.1200/JCO.2012.42.8771. Epub 2012 Oct 29.</citation>
    <PMID>23109696</PMID>
  </reference>
  <reference>
    <citation>Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006 Oct;93(10):1215-23.</citation>
    <PMID>16983741</PMID>
  </reference>
  <reference>
    <citation>Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012 Nov 1;30(31):3827-33. doi: 10.1200/JCO.2012.42.9597. Epub 2012 Sep 24. Erratum in: J Clin Oncol. 2013 Jan 20;31(3):399.</citation>
    <PMID>23008301</PMID>
  </reference>
  <reference>
    <citation>Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM; Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul;254(1):97-102. doi: 10.1097/SLA.0b013e3182196e1f.</citation>
    <PMID>21494121</PMID>
  </reference>
  <reference>
    <citation>Gao YH, Lin JZ, An X, Luo JL, Cai MY, Cai PQ, Kong LH, Liu GC, Tang JH, Chen G, Pan ZZ, Ding PR. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1153-60. doi: 10.1016/j.ijrobp.2014.07.021. Epub 2014 Oct 13.</citation>
    <PMID>25442042</PMID>
  </reference>
  <reference>
    <citation>Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CA, Nagtegaal ID, Wiggers T, Glimelius B. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer. 2013 Jun 7;13:279. doi: 10.1186/1471-2407-13-279.</citation>
    <PMID>23742033</PMID>
  </reference>
  <reference>
    <citation>Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.</citation>
    <PMID>25201358</PMID>
  </reference>
  <reference>
    <citation>Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.</citation>
    <PMID>26189067</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyung Hee University Hospital at Gangdong</investigator_affiliation>
    <investigator_full_name>Suk-Hwan Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Consolidation Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

